However, in agreement with our data, it has been found that the DFS is shorter in patients with ErbB-3 overexpression and that the level of ErbB-3 expression in primary BC seems to be involved in tumor progression from non-invasive to invasive tumors [36]. The gene discussed is ERBB3; the disease is breast cancer.